F.A. KHABIROV^1,2, T.I. KHAYBULLIN^1,2, E.V. GRANATOV², M.A. YAKUPOV², S.R. SHAKIRZANOVA²

¹Kazan State Medical Academy — Branch Campus of the FSBEI FPE RMACPE MOH Russia, 36 Butlerov Str., 420012 Kazan, Russian Federation

²Republic Clinical-diagnostic Center for Demyelinating Diseases, 13 Vatutin Str., Kazan, Russian Federation, 420021

  Khabirov F.A. — D. Sc. (medicine), Professor, Head of the Neurology Department, Head of the RCDCDS, tel. (843)278-97-28, e-mail: Farit.Нabirov@tatar.ru, ORCID ID: 0000-0002-2572-6970

Khaybullin T.I. — PhD (medicine), Associate Professor of the Department of Neurology and Manual Therapy, neurologist, tel. (843) 278-23-17, e-mail: timuur@gmail.com, ORCID ID: 0000-0002-5009-6683

Granatov E.V. — PhD (medicine), neurologist, tel. (843) 278-23-17, e-mail: rkdcdz@rkbvl.ru, ORCID ID: 0000-0002-0589-3288

Yakupov M.A. — neurologist, tel. (843) 278-23-17, e-mail: rkdcdz@rkbvl.ru, ORCID ID: 0000-0001-5899-9847

Shakirzanova S.R. — neurologist, tel. (843) 278-23-17, e-mail: rkdcdz@rkbvl.ru, ORCID ID: 0000-0003-2252-2259

Objective ― to explore modern publications on progressive forms of multiple sclerosis.

Material and methods. We have analyzed data of 13 scientific articles published from 2008 to 2018 in PubMed and «Practical Medicine» journal.

Results and conclusions. The remitting course of multiple sclerosis (MS) is transformed over time into a secondary progressive course characterized by gradual deterioration of the neurological deficit regardless of exacerbations. In 8-10% of patients, the disease initially has a progressive course (primary progressive MS). The progressive forms of MS make the main contribution to patient disability. Despite a large number of available pathogenetic means for MS, treatment of patients with progressive forms of the disease remains an unsolved task. The most significant means of treatment of patients with progressive forms of MS are symptomatic therapy and neurorehabilitation.

Key words: secondary progressive multiple sclerosis, primary progressive multiple sclerosis, perspective drugs.

(For citation: Khabirov F.A., Khaybullin T.I., Granatov E.V., Yakupov M.A., Shakirzanova S.R. Progressive forms of multiple sclerosis. Practical Medicine. 2018)

REFERENCES

1. Grand’Maison F., Yeung M., Morrow S.A., et al. Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches. Neural Regen Res, 2018, vol. 13 (11), pp. 1871-1874. doi: 10.4103/1673-5374.239432.
2. Moccia M., de Stefano N., Barkhof F. Imaging outcome measures for progressive multiple sclerosis trials. Mult. Scler, 2017, vol. 23 (12), pp. 1614-1626. doi: 10.1177/1352458517729456.
3. Popova E.V., Boyko A.N., Barabanova M.A. et al. Primary progressive sclerosis: the current state of the problem of making a timely diagnosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. Spetsvypuski, 2017, vol. 117, no. 10, pp. 35-40 (in Russ.). doi: 10.17116/jnevro201711710235-40.
4. Melendez-Torres G.J., Auguste P., Armoiry X., et al. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technol Assess, 2017, vol. 21 (52), pp. 1-352. doi: 10.3310/hta21520.
5. Kapoor R., Ho P.R., Campbell N., et al. ASCEND investigators. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol, 2018, vol. 17 (5), pp. 405-415. doi: 10.1016/S1474-4422(18)30069-3.
6. Kappos L., Bar-Or A., Cree B.A.C. et al. EXPAND investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, 2018, vol. 391 (10127), pp. 1263-1273. doi: 10.1016/S0140-6736(18)30475-6.
7. Hawker K., O’Connor P., Freedman M.S. et al. OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol, 2009, vol. 66 (4), pp. 460-471. doi: 10.1002/ana.21867
8. Mulero P., Midaglia L., Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther. Adv. Neurol Disord, 2018, 10; 11: 1756286418773025. doi: 10.1177/1756286418773025.
9. Montalban X., Hauser S.L., Kappos L. et al. ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N. Engl. J. Med, 2017, vol. 376 (3), pp. 209-220. doi: 10.1056/NEJMoa1606468.
10. Martinelli Boneschi F., Vacchi L., Rovaris M., et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev., 2013, May 31; (5). CD002127. doi: 10.1002/14651858.CD0021.
11. Chartier N., Epstein J., Soudant M. et al. Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study. Eur. J. Neurol., 2018, Jul 11. doi: 10.1111/ene.13748.
12. Zipoli V., Portaccio E., Hakiki B. et al. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. J. Neurol. Sci., 2008, vol. 266 (1-2), pp. 25-30.
13. Granatov E.V., Khabirov F.A., Khaybullin T.I. et al. Medical rehabilitation of patients with multiple sclerosis with motor and sensory disorders. Prakticheskaya meditsina, 2013, no. 1-1 (68), pp. 165-169 (in Russ.).